Opinion: Axa XL Re-Covéa – Caveat venditor
  • X
  • LinkedIn
  • Email
  • Show more sharing options
  • Print
  • X
  • LinkedIn
  • Email
  • Free Trial
  • Log in

Opinion: Axa XL Re-Covéa – Caveat venditor

Rachel Dalton
29 June 2021
  • X
  • LinkedIn
  • Email
  • Show more sharing options
  • Print
  • X
  • LinkedIn
  • Email
Covea_insurance_logo_paris_2021.png

On the surface of it, the prospective Covéa purchase of Axa XL Re looks like an advantageous match.

On one side of the possible transaction, we have a suitor that is champing at the bit to spend its EUR12bn excess capital, and whose central strategy is to diversify globally and by product line via reinsurance business.

Subscribers, log in here:

Fuel a smarter strategy with our actionable market intelligence

      • Gain a competitive edge and accelerate decision-making
      • Be empowered by insights that transform confusion to clarity
      • Uncover growth opportunities and prepare for potential threats
      • Fuel a smarter strategy for business growth
Request a free trial Already a subscriber? Log in now

Topics

Opinion M&A Axa XL
rachel dalton/rachel dalton ii red.png
Rachel Dalton
Lead Reporter
Contact
Gift this article